Tvardi Therapeutics Revenue and Competitors

Houston, TX USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Tvardi Therapeutics's estimated annual revenue is currently $3.6M per year.(i)
  • Tvardi Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Tvardi Therapeutics has 23 Employees.(i)
  • Tvardi Therapeutics grew their employee count by 28% last year.

Tvardi Therapeutics's People

NameTitleEmail/Phone
1
Co-founder Tvardi Therapeutics Inc.Reveal Email/Phone
2
CEOReveal Email/Phone
3
SVP R&DReveal Email/Phone
4
VP, CMCReveal Email/Phone
5
VP, DevelopmentReveal Email/Phone
6
Chief Medical OfficerReveal Email/Phone
7
Executive Director DevelopmentReveal Email/Phone
8
Sr. Clinical Project ManagerReveal Email/Phone
9
Senior Manager R&DReveal Email/Phone
10
CMC Program ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M11-8%N/AN/A
#2
$14.9M96-6%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$1.6M100%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.8M1850%N/AN/A
#7
$7.4M48-2%N/AN/A
#8
$0.8M50%N/AN/A
#9
$1.6M100%N/AN/A
#10
$16.3M10562%N/AN/A
Add Company

What Is Tvardi Therapeutics?

Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. Founded in 2017 and based in Houston, Texas, the company is led by experienced entrepreneurs, innovative scientists and dedicated physicians. Tvardi is focused on the development of inhibitors of STAT3, a key signaling molecule positioned at the intersection of many pathways controlling gene networks integral to the survival and immune sequestration of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic conditions. Tvardi is conducting a first-in-human Phase Ia dose-escalating study to determine safety and dosing for follow-on studies for its lead compound, TTI-101. Collectively, the societal and economic impact of STAT3-dependent disease is significant. Tvardi is highly motivated to develop safe and effective small molecule inhibitors of STAT3 for use across numerous diseases.

keywords:N/A

N/A

Total Funding

23

Number of Employees

$3.6M

Revenue (est)

28%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Tvardi Therapeutics News

2022-04-20 - Tvardi Therapeutics to Participate in Morgan Stanley Private ...

Tvardi Therapeutics to Participate in Morgan Stanley Private Company Biotech Corporate Access Day. April 28, 2022 04:00 PM Eastern Daylight Time.

2022-04-17 - Tvardi Therapeutics receives ODD for lead product TTI-101 to ...

Tvardi Therapeutics, a clinical-stage biopharmaceutical company, has announced receipt of orphan drug designation (ODD) from the US Food and...

2022-04-13 - Tvardi Therapeutics' TTI-101 Receives Orphan Drug ...

Tvardi Therapeutics' TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma. Published: Apr 21, 2022. April 21, 2022 12:00 UTC.

2021-06-23 - Tvardi Therapeutics Raises $74M in Series B Financing

Tvardi Therapeutics, Inc., a Houston, Texas-based clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, closed a $74m Series B financing. The round was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital, with participa ...

2020-07-26 - Tvardi Therapeutics Receives $5M in Grant Funding

Tvardi Therapeutics Inc., a Houston, TX-based clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, raised over $5m in non-dilutive grants. The three National Cancer Institute (NCI) funding awards are two Specialized Programs of Research Excellence (SPORE) gra ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.3M23N/AN/A
#2
$2.3M23N/AN/A
#3
$5.3M230%N/A
#4
$1.5M23-45%$4.4M
#5
$2.7M23-4%N/A